©TELIX – None of Telix’s product pipeline has received marketing authorization in any jurisdiction. Any use of Telix products is on an investigational basis or for use in approved clinical trials. TLX250 (Lu-177-DOTA-girentuximab) is a therapeutic Radiopharmaceutical that uses anti-CAIX girentuximab (just like the Imaging application) to deliver a therapeutic dose of targeted Radiation to clear cell renal cell carcinoma (ccRCC)
Kidney cancer is about twice as common in men than women and the risk of developing kidney cancer is increased by smoking, obesity, high blood pressure and diabetes. There are different types of kidney cancer notably the most common one, the clear cell renal cell carcinoma (ccRCC). 70-85% of kidney cancers are ccRCC and it has a high risk of Metastasis (spreading to other sites in the body). Promising results regarding the role of radiolabeled PET tracers as an Imaging modality for the evaluation of widespread disease and response to target and local therapies in patients with renal cancer have been observed.
Source: Telix Pharma
Approved treatments
No marketed radiotherapeutics available for this indication yet.
About kidney cancer
- What is Kidney Cancer – American Cancer Society
- Kidney Cancer, introduction – Cancer.Net
Clinical trials
*non-exhaustive list
Patient associations
Europe: A.R.Tu.R (FRA)
North America: National Kidney Foundation (USA)
Worldwide: International Kidney Cancer Coalition (IKCC)